參考文獻/References:
[1] NGUYEN P H,RAMAMOORTHY A,SAHOO B R,et al.Amyloid oligomers:a joint experimental/computational perspective on Alzheimer's disease,Parkinson's disease,typeⅡdiabetes,and amyotrophic lateral sclerosis[J].Chem Rev,2021,121(4):2545-2647.
[2] KING P H.Skeletal muscle as a molecular and cellular biomarker of disease progression in amyotrophic lateral sclerosis:a narrative review[J].Neural Regen Res,2024,19(4):747-753.
[3] XU Z,CHEN J,WANG P,et al.The role of peripheral β-amyloid in insulin resistance,insulin secretion, and prediabetes:in vitro and population-based studies[J].Front Endocrinol(Lausanne),2023,14:1195658.
[4] DENGLER-CRISH C M,ELEFTERIOU F.Shared mechanisms:osteoporosis and Alzheimer's disease?[J].Aging(Albany NY),2019,11(5):1317-1318.
[5] LLABRE J E,GIL C,AMATYA N,et al.Degradation of bone quality in a transgenic mouse model of Alzheimer's disease[J].J Bone Miner Res,2022,37(12):2548-2565.
[6] SUN Y,LI J,XIE X,et al.Macrophage-osteoclast associ-ations:origin,polarization,and subgroups[J].Front Immunol,2021,12:778078.
[7] EL-MASRI B M,ANDREASEN C M,LAURSEN K S,et al.Mapping RANKL- and OPG-expressing cells in bone tissue:the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect[J].Bone Res,2024,12(1):62.
[8] DE LEON-OLIVA D,BARRENA-BL?ZQUEZ S,JIM?NEZ-?LVAREZ L,et al.The RANK-RANKL-OPG system:a multifaceted regulator of homeostasis,immunity,and cancer[J].Medicina(Kaunas),2023,59(10):1752.
[9] CHEN Y,XIAO H,LIU Z,et al.Sirt1:An increasingly interesting molecule with a potential role in bone metabolism and osteoporosis[J].Biomolecules,2024,14(8):970.
[10] UDAGAWA N,KOIDE M,NAKAMURA M,et al.Osteoclast differentiation by RANKL and OPG signaling pathways[J].J Bone Miner Metab,2021,39(1):19-26.
[11] BLANGY A,BOMPARD G,GUERIT D,et al.The osteoclast cytoskeleton-current understanding and therapeutic perspectives for osteoporosis[J].J Cell Sci,2020,133(13):jcs244798.
[12] UMUR E,BULUT S B,YIGIT P,et al.Exploring the role of hormones and cytokines in osteoporosis development[J].Biomedicines,2024,12(8):1830.
[13] MATSUMOTO N,SEKIYA M,SUN-WADA G H,et al.The lysosomal V-ATPase a3 subunit is involved in localization of Mon1-Ccz1,the GEF for Rab7,to secretory lysosomes in osteoclasts[J].Sci Rep,2022,12(1):8455.
[14] CHENG X,TIAN W,YANG J,et al.Engineering approaches to manipulate osteoclast behavior for bone regener-ation[J].Mater Today Bio,2024,26:101043.
[15] CUI S,XIONG F,HONG Y,et al.APPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner[J].J Bone Miner Res,2011,26(5):1084-1098.
[16] XU C,ZHAO L,DONG C.A review of application of Aβ42/40 ratio in diagnosis and prognosis of Alzheimer's disease[J].J Alzheimers Dis,2022,90(2):495-512.
[17] LI S,YANG B,TEGUH D,et al.Amyloid β peptide enhances RANKL-induced osteoclast activation through NF-κB,ERK,and calcium oscillation signaling[J].Int J Mol Sci,2016,17(10):1683.
[18] ALIPRANTIS A O,UEKI Y,SULYANTO R,et al.NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism[J].J Clin Invest,2008,118(11):3775-3789.
[19] XU S,CAO X,YU Z,et al.Nicorandil Inhibits osteoclast formation base on NF-κB and p-38 MAPK signaling pathways and relieves ovariectomy-induced bone loss[J].Front Pharmacol,2021,12:726361.
[20] YANG X,ZENG J,XIE K,et al.Advanced glycation end product-modified low-density lipoprotein promotes pro-osteogenic reprogramming via RAGE/NF-κB pathway and exaggerates aortic valve calcification in hamsters[J].Mol Med, 2024,30(1):76.
[21] ZHOU J,LIU S,BI S,et al.The RAGE signaling in osteoporosis[J].Biomed Pharmacother,2023,165:115044.
[22] LIU J,TING J P,AL-AZZAM S,et al.Therapeutic advances in diabetes,autoimmune,and neurological diseases[J].Int J Mol Sci,2021,22(6):2805.
[23] ZHOU Z,IMMEL D,XI C X,et al.Regulation of osteoclast function and bone mass by RAGE[J].J Exp Med,2006,203(4):1067-1080.
[24] LIU T,WANG Y,QIAN B,et al.Potential metabolic pathways involved in osteoporosis and evaluation of fracture risk in individuals with diabetes[J].Biomed Res Int,2024,2024:6640796.
[25] JIANG T,XIA T,QIAO F,et al.Role and regulation of transcription factors in osteoclastogenesis[J].Int J Mol Sci,2023,24(22):16175.
[26] FEDELE E.Anti-amyloid therapies for Alzheimer's disease and the amyloid cascade hypothesis[J].Int J Mol Sci,2023,24(19):14499.
[27] MATSUO K,IRIE N.Osteoclast-osteoblast communica-tion[J].Arch Biochem Biophys,2008,473(2):201-209.
[28] HART N H,NEWTON R U,TAN J,et al.Biological basis of bone strength: anatomy, physiology and measurement[J].J Musculoskelet Neuronal Interact,2020,20(3):347-371.
[29] PAN J X,TANG F,XIONG F,et al.APP promotes osteoblast survival and bone formation by regulating mitochon-drial function and preventing oxidative stress[J].Cell Death Dis,2018,9(11):1077.
[30] XIA W F,JUNG J U,SHUN C,et al.Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit,which are ameliorated by N-acetyl-L-cysteine[J].J Bone Miner Res,2013,28(10):2122-2135.
[31] MCGRATH C,LITTLE-LETSINGER S E,SANKARAN J S,et al.Exercise increases bone in SEIPIN deficient lipodystrophy,despite low marrow adiposity[J].Front Endocrinol(Lausanne),2021,12:782194.
[32] LABUSCA L.Adipose tissue in bone regeneration-stem cell source and beyond[J].World J Stem Cells,2022,14(6):372-392.
[33] PETRINA M,MARTIN J,BASTA S.Granulocyte macrophage colony-stimulating factor has come of age:from a vaccine adjuvant to antiviral immunotherapy[J].Cytokine Growth Factor Rev,2021,59:101-110.
[34] ROBLING A G,BONEWALD L F.The osteocyte:new insights[J].Annu Rev Physiol,2020,82:485-506.
[35] SHEN L,HU G,KARNER C M.Bioenergetic metabolism in osteoblast differentiation[J].Curr Osteoporos Rep,2022,20(1):53-64.
相似文獻/References:
[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的
胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]韓艷,溫利平,劉娜,等.補腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):7.
[3]李學(xué)朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):12.
[4]陳冠軍,陳揚,莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng)
在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[5]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):27.
[6]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證
患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(03):19.
[7]項旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(03):20.
[8]史曉林,李春雯,張志強.弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):5.
[9]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機制研究[J].中醫(yī)正骨,2014,26(09):21.
Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):21.
[10]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的
相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(03):16.